Indeed, the rationale for the inhibition of the PI3K/Akt/mTOR pathway in targeted cancer therapy is compelling and is supported by four major elements of clinical evidence: the activation of the pathway is common in multiple cancers; its activation is found throughout carcinogenesis; and its activation is a poor prognostic factor and may also confer resistance to chemotherapy [102]. This evidence concerns the gene MTOR and cancer.